Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries’ one of the wholly owned subsidiaries has agreed to acquire shares of Tarsius Pharma (Tarsius), Israel, by way of subscription of 345,622 ordinary shares of nominal value of NIS 0.01 each, representing 18.75% of shares of Tarsius, on a fully diluted basis.

Tarsius is an Israel based early stage Research and Development (R&D) company focusing on development of drug candidates in the field of Ophthalmology. The cost of acquisition is $3 million and indicative time period for completion of the acquisition is before September 15, 2018.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.